New COO for Celgene

pharmafile | March 1, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene 

Celgene released in a statement that its Chief Operating Officer and President, Jacqualyn “Jackie” Fouse, will retire from her position. She will continue to fulfil her role until 1 April and continue to serve as strategic advisor beyond this period onto 1 June.

Fouse’s role will be filled by Scott Smith, who takes the role after having launched Celgene’s Inflammation & Immunocology franchise and will take up the post immediately after Fouse vacates the role on 1 April. His position, in turn, will be filled by Terrie Curran – who will take the position of President, Global I&I Franchise.

Smith has been with Celgene for over 11 years, performing the roles of Senior Vice President of Immunology and the aforementione role. Prior this he had worked at Pfizer and Biovail.

“Scott is a tremendous leader with extensive industry experience and his teams have consistently delivered outstanding results,” said Mark Alles, Celgene CEO. “Our entire organization will benefit from Scott’s business expertise, strategic leadership, and focus on operational excellence.”

Ben Hargreaves

Related Content


NICE recommends Celgene’s REVLIMID for multiple myeloma

NICE has issued a Final Appraisal Document (FAD) recommending Celgene’s REVLIMID (lenalidomide) as maintenance treatment …

NICE opts to reject Celgene’s Revlimid for newly diagnosed multiple myeloma after an autologous stem cell transplant

It has emerged that NICE has opted to reject Celgene’s Revlimid (lenalidomide) for the maintenance …


NICE recommends Celgene’s Revlimid combo for follicular lymphoma

NICE has chosen to recommend Celgene’s Revlimid (lenalidomide) for use on the NHS, it has …

Latest content